Octreotide FOLFOX chemotherapy efficacy in treatment of advanced colorectal cancer.doc

 PAGE \* MERGEFORMAT 13 Octreotide FOLFOX chemotherapy efficacy in treatment of advanced colorectal cancer Of: Xudong Yun, Zhang Nan Zheng, Xu Yongmao [Abstract] Objective To observe the octreotide (OCT) combined FOLFOX chemotherapy treatment of advanced colorectal cancer clinical efficacy and safety. Methods 58 patients with advanced colorectal cancer were randomly divided into 2 groups: treatment group 30 cases, OCT combined with FOLFOX chemotherapy in the control 28 cases, the use of FOLFOX chemotherapy, at least 2 cycles of treatment, the curative effect, physical condition (KPS score, serum carcinoembryonic antigen (CEA and adverse reactions were observed. Results The response rate in treatment group, KPS score improvement rate, serum reduce the rate of CEA-positive was significantly higher (P lt;0.05. There were no serious side effects. Conclusion OCT FOLFOX chemotherapy combined with advanced colorectal cancer can improve the efficacy, side effects are tolerable. [Keywords:] colorectal cancer, chemotherapy, octreotide Abstract: Objective To investigate the efficacy and safety of octreotide (OCT) combined with FOLFOX regimen in the treatment of advanced colorectal cancer. Methods 58 cases of advanced colorectal cancer were randomized into treatment group (n = 30), treated with OCT combined with FOLFOX regimen and the control group (n = 28), treated with FOLFOX regimen. After at least 2 courses, the recent efficacy, KPS scores, serum CEA and adverse reactions were analyzed. Results The recent efficacy rate was significantly higher in the treatment group ( 50.00%) than in the control group (39.30%) (P lt;0.05). The KPS score improvement of the treatment group (60.00%) was obviously superior to that of the control group (42.86%) (P lt;0.05). The serum CEA-positive reduction rate of the treatment group (46.96%) was significantly larger than that of the control group (30.63%) (P lt;0.05). There were no serious adverse reactions in either group. C